张晓辉，1988年生，籍贯河南周口，系统医学研究院研究员，博士生导师。2008年考入河南科技大学大学生物科学专业，2012年获得学士学位。2012年在昆明理工大学大学生物化学与分子生物学专业攻读硕士学位。2016年在华东师范大学生物化学与分子生物学专业攻读博士学位，从事基因编辑技术开发与优化研究。2020年博士毕业后受聘华东师范大学生命科学学院副研究员，从事基因编辑工具的开发、优化以及在疾病动物模型和基因治疗方面的应用。

拟从酶定向进化、蛋白理性设计和DNA损伤修复机制等角度入手探索现有基因编辑工具技术瓶颈的解决方案，并尝试在体基因治疗可行性，为临床重大疾病基因治疗提供可行性方案。

1. Zihan Zhang , Rui Zheng , Zhoutong Chen , Xia Zhan , Xiaoliang Fang , Meizhen Liu , Yongmei Li , Yonghu Xu , Dali Li , Hongquan Geng , Xiaohui Zhang* and Guofeng Xu*. Differences in renal cortex transcriptional profiling of wild-type and novel type B cystinuria model rats. Urolithiasis 50, 279–291 (2022). (IF=2.861)

2. Xiaohui Zhang#, Biyun Zhu#, Liang Chen#, Ling Xie, Weishi Yu, Ying Wang, Linxi Li, Shuming Yin, Lei Yang, Handan Hu, Honghui Han, Yongmei Li, Liren Wang, Geng Chen, Xueyun Ma, Hongquan Geng, Wanfeng Huang, Xiufeng Pang, Zuozhen Yang, Yuxuan Wu, Stefan Siwko, Ryo Kurita, Yukio Nakamura, Li Yang, Mingyao Liu and Dali Li*. Dual base editor catalyzes both cytidine and adenine base conversions in human cells. Nat. Biotechnol. 38, 856–860(2020). (Highlighted by Nature Reviews Genetics “Multitasking for base editors”). (IF=36.558, ESI 1%)

3. Xiaohui Zhang#, Liang Chen#, Biyun Zhu#, Liren Wang, Caiyu Chen, Mengjia Hong, Yifan Huang, Huiying Li, Honghui Han, Bailian Cai, Weishi Yu, Shuming Yin, Lei Yang, Zuozhen Yang, Meizhen Liu, Ying Zhang, Zhiyong Mao, Yuxuan Wu, Mingyao Liu and Dali Li*. Increasing the efficiency and targeting range of cytidine base editors through fusion of a single-strand DNA binding protein domain. Nat. Cell Biol. 22, 740–750 (2020). (Highlighted by Nature Cell Biology “Base editing goes into hyperdrive”.). (IF=28.82)

4. Lei Yang#, Xiaohui Zhang#, Liren Wang#, Shuming Yin#, Biyun Zhu, Ling Xie, Qiuhui Duan, Huiqiong Hu,Rui Zheng, Yu Wei, Liangyue Peng, Honghui Han,Jiqin Zhang, Wenjuan Qiu, Hongquan Geng,Stefan Siwko, Xueli Zhang, Mingyao Liu, Dali Li*. Increasing targeting scope of adenosine base editors in mouse and rat embryos through fusion of TadA deaminase with Cas9 variants. Protein & Cell 9, 814-819 (2018). (Cover story, Highlight by Protein & Cell ). (IF=7.575)

5. Xiaohui Zhang#, Liren Wang#, Mingyao Liu* and Dali Li*. CRISPR/Cas9 system: a powerful technology for in vivo and ex vivo gene therapy. Sci. China Life Sci. 60(5):468-475 (2017) . (IF=3.085)

6. Zhang, X.-H.#, Tee, L.Y., Wang, X.-G., Huang, Q.-S. & Yang, S.-H*.. Off-target effects in CRISPR/Cas9-mediated genome engineering. Molecular Therapy-Nucleic Acids 4, e264 (2015). (IF=5.048, ESI 1%)